# Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

- Source: PR Newswire M&A
- Published: 2026-11-06T02:03:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/johnson--johnson-announces-us-fda-approval-of-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-as-first-and-only-dual-targeted-therapy-for-advanced-head-and-neck-cancer-302931583.html
- Canonical: https://groundlevelnews.com/story/johnson-johnson-announces-u-s-fda-approval-of-rybrevant-faspro-amivant-75e957/

Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1 First advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer in a...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._